| ID | 1119 |
| Name of the vaccine | TYPHIBEV |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 months to 45 years |
| Description of the vaccine | Formulated with Vi polysaccharide conjugated to a carrier protein (CRM197). |
| Name of the manufacturer | Biological E |
| Name of the manufacturing country | India |
| Year of manufacture | 2020 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | 79-85% efficacy against typhoid fever. |
| Vaccine formulation | NA |
| Dosage | Single dose and a booster dose may be given after 3 years. |
| Mechanism of action | Through conjugation, TCVs are able to stimulate parts of the immune system and give long lasting immunity. |
| Route of administration | Intramuscular |
| Indications | Long term protection against typhoid fever. |
| Export | Allowed to be purchased by United Nations agencies. |
| Approval | WHO pre-qualified |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.coalitionagainsttyphoid.org/the-issues/typhoid-vaccines/ |
| Other name | NA |
| Additional Links | https://www.coalitionagainsttyphoid.org/wp-content/uploads/2021/06/TYPHIBEV-QA_May-2021.pdf
|